ADDITIONAL MECHANISMS BY WHICH NON-TARGETED GENES COMPENSATE FOR SPECIFIC GENE THERAPY DIRECTED TOWARDS BCL-2 IN a PROSTATE CANCER MODEL a Summary

doi 10.32392/biomed.9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Knowledge Enterprise Journals

Related search

Prostate-Specific Membrane Antigen–Directed Therapy for Metastatic Castration-Resistant Prostate Cancer

Cancer Journal
Cancer ResearchOncology
2016English

Targeted Molecular-Genetic Imaging and Ligand-Directed Therapy in Aggressive Variant Prostate Cancer

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2016English

Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen in a Micrometastatic Model of Prostate Cancer

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2016English

PDGFRβ-specific Affibody-Directed Delivery of a Photosensitizer, IR700, Is Efficient for Vascular-Targeted Photodynamic Therapy of Colorectal Cancer

Drug Delivery
MedicinePharmaceutical Science
2017English

Targeting the BCL-2 Family for Cancer Therapy

Expert Opinion on Therapeutic Targets
Molecular MedicineDrug DiscoveryClinical BiochemistryPharmacology
2012English

Development of a Nanotechnology Platform for Prostate Cancer Gene Therapy

2011English

Targeted Therapy of Cancer: New Roles for Pathologists—prostate Cancer

Modern Pathology
Forensic MedicinePathology
2008English

BH4 Domain of BCL-2 as a Novel Target for Cancer Therapy

Drug Discovery Today
Drug DiscoveryPharmacology
2016English

Functional Characterization of a Novel Prostate-Specific Gene PrLZ in Prostate Cancer

2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy